BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 18, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Votrient pazopanib: Preliminary Phase II data

Researchers at the Fondazione IRCCS Istituto Nazionale dei Tumori reported preliminary data from 18 patients in an ongoing, open-label, Italian Phase II trial showing that once-daily 800 mg oral pazopanib led to tumor shrinkage in 4 patients, with 12 patients experiencing necrosis of their...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >